Aberdeen Group plc Cuts Stock Position in Rallybio Corporation $RLYB

Aberdeen Group plc lessened its holdings in Rallybio Corporation (NASDAQ:RLYB) by 7.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,595,262 shares of the company’s stock after selling 131,805 shares during the period. Aberdeen Group plc’s holdings in Rallybio were worth $539,000 as of its most recent SEC filing.

Rallybio Stock Down 3.4%

Rallybio stock opened at $0.54 on Friday. The firm has a 50-day moving average price of $0.57 and a two-hundred day moving average price of $0.43. The firm has a market capitalization of $22.36 million, a price-to-earnings ratio of -0.57 and a beta of -1.10. Rallybio Corporation has a 52-week low of $0.22 and a 52-week high of $1.24.

Rallybio (NASDAQ:RLYB) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. The company had revenue of $0.21 million during the quarter. Rallybio had a negative net margin of 5,473.33% and a negative return on equity of 71.66%. Research analysts expect that Rallybio Corporation will post -1.34 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on RLYB shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rallybio in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Rallybio from a “hold” rating to a “sell” rating in a research note on Sunday, October 12th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $5.00.

Rallybio Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.